Annual EBITDA
-$36.23 M
+$2.50 M+6.47%
December 31, 2023
Summary
- As of February 8, 2025, UBX annual EBITDA is -$36.23 million, with the most recent change of +$2.50 million (+6.47%) on December 31, 2023.
- During the last 3 years, UBX annual EBITDA has risen by +$52.88 million (+59.34%).
- UBX annual EBITDA is now -93.82% below its all-time high of -$18.69 million, reached on December 31, 2016.
Performance
UBX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$6.26 M
-$1.21 M-23.86%
September 30, 2024
Summary
- As of February 8, 2025, UBX quarterly EBITDA is -$6.26 million, with the most recent change of -$1.21 million (-23.86%) on September 30, 2024.
- Over the past year, UBX quarterly EBITDA has increased by +$7.64 million (+54.95%).
- UBX quarterly EBITDA is now -333.07% below its all-time high of $2.69 million, reached on December 31, 2022.
Performance
UBX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$20.99 M
+$7.64 M+26.69%
September 30, 2024
Summary
- As of February 8, 2025, UBX TTM EBITDA is -$20.99 million, with the most recent change of +$7.64 million (+26.69%) on September 30, 2024.
- Over the past year, UBX TTM EBITDA has increased by +$8.43 million (+28.66%).
- UBX TTM EBITDA is now -134.67% below its all-time high of -$8.95 million, reached on March 31, 2017.
Performance
UBX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
UBX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +6.5% | +55.0% | +28.7% |
| 3 y3 years | +59.3% | -333.1% | +45.8% |
| 5 y5 years | +51.2% | -333.1% | +45.8% |
UBX EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +33.7% | -333.1% | +64.2% | at high | +63.8% |
| 5 y | 5-year | at high | +59.3% | -333.1% | +76.9% | at high | +76.4% |
| alltime | all time | -93.8% | +59.3% | -333.1% | +76.9% | -134.7% | +76.4% |
Unity Biotechnology EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$6.26 M(+23.9%) | -$20.99 M(-26.7%) |
| Jun 2024 | - | -$5.06 M(-9.1%) | -$28.64 M(-24.3%) |
| Mar 2024 | - | -$5.56 M(+35.4%) | -$37.84 M(+4.5%) |
| Dec 2023 | -$36.23 M(-6.5%) | -$4.11 M(-70.5%) | -$36.22 M(+23.1%) |
| Sep 2023 | - | -$13.91 M(-2.5%) | -$29.43 M(+5.8%) |
| Jun 2023 | - | -$14.26 M(+261.2%) | -$27.83 M(+10.4%) |
| Mar 2023 | - | -$3.95 M(-246.9%) | -$25.20 M(-34.9%) |
| Dec 2022 | -$38.73 M(-29.2%) | $2.69 M(-121.8%) | -$38.73 M(-23.5%) |
| Sep 2022 | - | -$12.31 M(+5.8%) | -$50.62 M(-5.0%) |
| Jun 2022 | - | -$11.63 M(-33.4%) | -$53.26 M(-8.1%) |
| Mar 2022 | - | -$17.48 M(+90.1%) | -$57.92 M(+6.0%) |
| Dec 2021 | -$54.67 M(-38.6%) | -$9.20 M(-38.5%) | -$54.67 M(-13.8%) |
| Sep 2021 | - | -$14.95 M(-8.3%) | -$63.45 M(-15.1%) |
| Jun 2021 | - | -$16.30 M(+14.6%) | -$74.73 M(-1.9%) |
| Mar 2021 | - | -$14.22 M(-20.9%) | -$76.19 M(-14.5%) |
| Dec 2020 | -$89.10 M | -$17.98 M(-31.4%) | -$89.10 M(+0.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2020 | - | -$26.23 M(+47.7%) | -$88.40 M(+6.2%) |
| Jun 2020 | - | -$17.76 M(-34.6%) | -$83.25 M(-5.7%) |
| Mar 2020 | - | -$27.14 M(+57.0%) | -$88.28 M(+8.3%) |
| Dec 2019 | -$79.51 M(+7.1%) | -$17.28 M(-18.0%) | -$81.49 M(-5.0%) |
| Sep 2019 | - | -$21.07 M(-7.6%) | -$85.75 M(+3.5%) |
| Jun 2019 | - | -$22.80 M(+12.0%) | -$82.86 M(+5.4%) |
| Mar 2019 | - | -$20.34 M(-5.5%) | -$78.58 M(+5.9%) |
| Dec 2018 | -$74.22 M(+67.5%) | -$21.54 M(+18.5%) | -$74.22 M(+14.2%) |
| Sep 2018 | - | -$18.18 M(-1.8%) | -$65.00 M(+11.2%) |
| Jun 2018 | - | -$18.52 M(+15.9%) | -$58.45 M(+13.9%) |
| Mar 2018 | - | -$15.98 M(+29.7%) | -$51.34 M(+15.9%) |
| Dec 2017 | -$44.30 M(+137.0%) | -$12.32 M(+5.9%) | -$44.30 M(+38.5%) |
| Sep 2017 | - | -$11.63 M(+2.0%) | -$31.98 M(+57.2%) |
| Jun 2017 | - | -$11.40 M(+27.5%) | -$20.35 M(+127.5%) |
| Mar 2017 | - | -$8.95 M | -$8.95 M |
| Dec 2016 | -$18.69 M | - | - |
FAQ
- What is Unity Biotechnology annual EBITDA?
- What is the all time high annual EBITDA for Unity Biotechnology?
- What is Unity Biotechnology annual EBITDA year-on-year change?
- What is Unity Biotechnology quarterly EBITDA?
- What is the all time high quarterly EBITDA for Unity Biotechnology?
- What is Unity Biotechnology quarterly EBITDA year-on-year change?
- What is Unity Biotechnology TTM EBITDA?
- What is the all time high TTM EBITDA for Unity Biotechnology?
- What is Unity Biotechnology TTM EBITDA year-on-year change?
What is Unity Biotechnology annual EBITDA?
The current annual EBITDA of UBX is -$36.23 M
What is the all time high annual EBITDA for Unity Biotechnology?
Unity Biotechnology all-time high annual EBITDA is -$18.69 M
What is Unity Biotechnology annual EBITDA year-on-year change?
Over the past year, UBX annual EBITDA has changed by +$2.50 M (+6.47%)
What is Unity Biotechnology quarterly EBITDA?
The current quarterly EBITDA of UBX is -$6.26 M
What is the all time high quarterly EBITDA for Unity Biotechnology?
Unity Biotechnology all-time high quarterly EBITDA is $2.69 M
What is Unity Biotechnology quarterly EBITDA year-on-year change?
Over the past year, UBX quarterly EBITDA has changed by +$7.64 M (+54.95%)
What is Unity Biotechnology TTM EBITDA?
The current TTM EBITDA of UBX is -$20.99 M
What is the all time high TTM EBITDA for Unity Biotechnology?
Unity Biotechnology all-time high TTM EBITDA is -$8.95 M
What is Unity Biotechnology TTM EBITDA year-on-year change?
Over the past year, UBX TTM EBITDA has changed by +$8.43 M (+28.66%)